[Moving irradiation in the combined radiation treatment of cervical cancer]

Application of moving telegamma therapy as an adjunct to the associated radiation treatment in 399 patients allowed an increase of the dosage up to 6500 rad in the parametrium area. A 5-year survival in stage I was 91.6 +/- 10.5%, in stage II--63.3 +/- 4.7% and in stage III--48 +/- 5.6%. Late postirradiation rectitis was noted in 24 patients, cystitis--in 8 and rectal fistula--in 7.